Knowledge-driven interpretable neural networks for mechanistic insight.

Publication date: Jul 24, 2026

Analyzing omics data in the context of pathway knowledge is critical for understanding the molecular mechanisms underlying pathological changes. However, current pathway analysis methods do not model the detailed mechanistic nature of biological interactions, limiting the understanding of pathway behavior to a relatively shallow level. To address this issue, we present a knowledge-driven machine learning framework that embeds features into pathway graphs and models reactions analytically, producing interpretable feature hierarchies and subnetworks in which functional associations are estimated to model biological interactions. The approach is agnostic to feature selection, enabling the use of full omics datasets without discarding weak signals. Applications to breast cancer microRNA-gene regulation data and COVID-19 metabolomics data highlight immune and metabolic pathways relevant to disease progression. This framework bridges predictive modeling with mechanistic interpretation and offers a foundation for integrative pathway analysis.

Open Access PDF

Concepts Keywords
Agnostic Analyzing
Graphs Biological
Metabolomics Context
Models Critical
Nature Driven
Insight
Interactions
Interpretable
Knowledge
Mechanistic
Networks
Neural
Omics
Pathway
Understanding

Semantics

Type Source Name
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH COVID-19
disease MESH disease progression
pathway REACTOME Signal Transduction
drug DRUGBANK Platinum
drug DRUGBANK Resiniferatoxin
disease MESH tumor
drug DRUGBANK Genistein
drug DRUGBANK L-Tyrosine
pathway REACTOME Signal attenuation
disease MESH shock
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH inflammation
drug DRUGBANK Guanosine
disease MESH cytokine storms
pathway REACTOME Metabolism
pathway KEGG Viral replication
drug DRUGBANK L-Tryptophan
pathway KEGG Tryptophan metabolism
disease MESH immune suppression
drug DRUGBANK Dinoprostone
disease MESH viral infections
disease MESH acute respiratory distress syndrome
drug DRUGBANK Formic Acid
drug DRUGBANK L-Alanine
drug DRUGBANK Serine
drug DRUGBANK Activated charcoal
disease MESH mitochondrial dysfunction
drug DRUGBANK Arachidonic Acid
disease MESH infections
drug DRUGBANK Omega-3 fatty acids
disease MESH PGs
disease MESH fever
disease MESH pain
drug DRUGBANK Leukotriene B4
disease MESH acute lung injury
disease MESH pulmonary fibrosis
drug DRUGBANK Succinic acid
drug DRUGBANK Prostaglandin D2
drug DRUGBANK Serotonin
drug DRUGBANK Palmitic Acid
drug DRUGBANK Sphingosine
drug DRUGBANK Phosphate ion
drug DRUGBANK Melatonin
drug DRUGBANK Epoprostenol
disease MESH lung inflammation
drug DRUGBANK L-Arginine
pathway KEGG Nitrogen metabolism
drug DRUGBANK L-Citrulline
drug DRUGBANK Ornithine
drug DRUGBANK Urea
drug DRUGBANK Nitric Oxide
drug DRUGBANK Levocarnitine
drug DRUGBANK Acetylcarnitine
pathway REACTOME Ketone body metabolism
drug DRUGBANK Folic Acid
pathway REACTOME Nucleotide biosynthesis
drug DRUGBANK Lactic Acid
disease MESH hypoxia
drug DRUGBANK Angiotensin II
drug DRUGBANK Ranitidine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Saquinavir
disease MESH included
disease MESH aids
disease MESH hops
drug DRUGBANK Flunarizine

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *